Professor Artur Schmidtchen
Professor of Dermatology and Skin Biology
Principal Investigator, Dermatology and Innate Immunity Laboratory
- Dr Rathi Saravanan, Senior Research Fellow
- Dr Sunil Shankar Adav, Senior Research Fellow
- Dr Bani Kaur Suri, Research Fellow
- Miss Kerk Swat Kim, Research Assistant
- Mr Choong Yeu Khai, Research Assistant
- Miss Lim Yun Shiang, Research Assistant
- Mr. Lian Yilong, PhD Student
- Mr. Lim Chun Hwee, PhD Student
Professor Artur Schmidtchen is Professor of Dermatology and Skin Biology in Lee Kong Chian School of Medicine, Nanyang Technological University. After completing his PhD studies in the area of medical chemistry, a postdoctoral stay at UCLA (University of California, Los Angeles), and medical studies at Lund University followed by an internship as MD, he joined the Department of Dermatology in 1996.
As senior consultant from 2004 he has been particularly involved in dermatologic surgery, and seeing patients with non-healing ulcers and inflammatory skin diseases. The research has focused on defining novel human innate immunity systems, and their crosstalk with hemostasis and inflammatory pathways in skin, during wounding and infection. Several discoveries have been further developed; Prof Schmidtchen is co-founder of DermaGen AB and Ximmune AB, and founder of in2cure AB, companies aiming at commercialising inventions from the research group.
Prof Schmidtchen has published over 100 papers, in journals such as JBC, PNAS PLOS Pathogens, Biochemistry, and Blood. His research has been awarded several times in Sweden; young investigators prize from the Medical Faculty and University Hospital in Lund, the Schyberg Foundation, the Sandberg Foundation for translational research, Ellis and Ivar Janzons award from the Swedish Medical Association, and the prestigious Fernström award for young investigators. He is a board member of the Swedish Welander Foundation, and co-editor of Acta Dermato-Venereologica.
There are great and unmet medical needs within areas of dermatology and infective disease. Many diseases, such as atopic dermatitis (AD), chronic ulcers and acne, are characterised by excessive inflammation, and reflect a complex pathogenesis involving barrier dysfunction, innate as well as adaptive immunity, and microbial influence. In addition, burn wound infections, as well as postoperative infections cause significant morbidity and risk for invasive infections and sepsis. There is a great need for conceptually novel treatment approaches for infective-inflammatory diseases.
In the normal, healthy state various evolutionary conserved host defense systems control both bacteria and inflammation. Research on innate immunity systems in skin, wounds, and in blood, has led to the discovery of new classes of bioactive host defence peptides (HDPs) and proteins with combined antimicrobial and immunomodulatory activities. In basic studies, the structure and function of these HDPs are studied in health and disease.
From a clinical and therapeutic perspective, the knowledge is utilised in the development of novel therapeutics in skin and wounds, as well as for various systemic applications targeting infective-inflammatory disease.
Overall, the goal is to establish a platform within skin biology, wounding, infection-inflammation and innate immunity, with the aim of creating a strong collaborative environment facilitating translation of basic discoveries to the clinic and industry.
van der Plas M, Bhongir R, Kjellström S, Siller H, Kasetty G, Mörgelin M, Schmidtchen A. Pseudomonas aeruginosa elastase cleaves a C-terminal peptide from human thrombin that inhibits host inflammatory responses. 2016. Nature Communications, 16;7:11567.
Hansen F, Kalle-Brune M, van der Plas MJA, Strömdahl AC, Malmsten M, Mörgelin M, Schmidtchen A. The thrombin-derived host defense peptide GKY25 inhibits endotoxin-induced responses through interactions with lipopolysaccharide and macrophages/monocytes. Journal of Immunology, 2015, 194:5397-5406.
Kasetty G, Kalle M, Mörgelin M, Brune JC, Schmidtchen A. Anti-endotoxic and antibacterial effects of a dermal substitute coated with host defense peptides. Biomaterials, 2015, 53, 415e425
Papareddy P, Kalle M, Bhongir R, Mörgelin M, Malmsten M, Schmidtchen A. Antimicrobial effects of helix D-derived peptides of human antithrombin III. Journal of Biological Chemistry, 2014, 24;289(43):29790-800.
Papareddy P, Kalle M, Sørensen OE, Malmsten M, Mörgelin M, Schmidtchen A. The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis. PLoS Pathog. 2013 Dec;9(12):e1003803.
Proteolytic activation transforms heparin cofactor II into a host defense molecule. Kalle M, Papareddy P, Kasetty G, Tollefsen DT, Malmsten M, Mörgelin M, Schmidtchen A. Journal of Immunology, 2013, 190, 6303-6310
Papareddy P, Rydengård V, Pasupuleti M, Walse B, Mörgelin M, Chalupka A, Malmsten M, Schmidtchen A. Proteolysis of human thrombin generates novel host defense peptides. PLoS Pathog. 2010 Apr 22;6(4):e1000857.
Rydengård V, Shannon O, Lundqvist K, Kacprzyk, L, Chalupka A, Olsson, AK, Mörgelin M, Jahnen-Dechent W, Malmsten M, Schmidtchen A. Histidine-rich glycoprotein protects from systemic Candida infection. PLoS Pathogens, 2008, 4: e1000116.
Nordahl E, Rydengård V, Mörgelin M, Schmidtchen A. Domain 5 of high molecular weight kininogen is antibacterial, Journal of Biological Chemistry. 2005, 280:34832-34839.
Nordahl E, Rydengård V, Nyberg P, Nitsche DP, Mörgelin M, Malmsten M., Björck L, Schmidtchen A. Activation of the complement system generates antibacterial peptides. Proceedings of the National Academy of Sciences USA. 2004, 30:16879-16884.